Justin T Low1,2, Quinn T Ostrom1,2,3,4, Gino Cioffi3,5, Corey Neff2,3, Kristin A Waite2,5, Carol Kruchko2, Jill S Barnholtz-Sloan2,5,6. 1. The Preston Robert Tisch Brain Tumor Center, Duke University School of Medicine, Durham, North Carolina, USA. 2. Department of Neurosurgery, Duke University School of Medicine, Durham, North Carolina, USA. 3. Central Brain Tumor Registry of the United States, Hinsdale, Illinois, USA. 4. Duke Cancer Institute, Duke University Medical Center, Durham, North Carolina, USA. 5. Trans Divisional Research Program (TDRP), Division of Cancer Epidemiology and Genetics (DCEG), National Cancer Institute, Bethesda, Maryland, USA. 6. Center for Biomedical Informatics & Information Technology (CBIIT), National Cancer Institute, Bethesda, Maryland,USA.
Abstract
Background: The Central Brain Tumor Registry of the United States (CBTRUS) contains information on all primary brain and other central nervous system (CNS) tumors diagnosed in the United States (US). Here we summarize the 2021 CBTRUS annual statistical report for clinicians. Methods: Incidence survival data are obtained from the Centers for Disease Control's National Program of Cancer Registries (NPCR) and National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) program. Survival data are obtained from NPCR. Mortality data are obtained from the National Vital Statistics System. Incidence and mortality rates are age-adjusted using the 2000 US population and presented per 100,000 population. Results: An annual average of 86,355 cases of primary malignant and nonmalignant CNS tumors were diagnosed over the period 2014-2018, corresponding to an average annual age-adjusted incidence rate of 24.25. The most commonly occurring malignant tumor was glioblastoma (14.3%), and the most common predominately nonmalignant tumor was meningioma (39%). Over the 2014-2018 period, there were 16,606 annual average deaths due to malignant primary CNS tumors, corresponding to an average annual age-adjusted mortality rate of 4.43. In this report we detail key incidence, survival, and mortality statistics for major primary CNS tumor histologies, highlighting relevant differences by age, sex, and race. Conclusions: This summary describes the most up to date population-based incidence of primary malignant and nonmalignant brain and other CNS tumors in the US, and mortality and survival for primary malignant tumors and aims to serve as a useful resource for clinicians. Published by Oxford University Press 2022.
Background: The Central Brain Tumor Registry of the United States (CBTRUS) contains information on all primary brain and other central nervous system (CNS) tumors diagnosed in the United States (US). Here we summarize the 2021 CBTRUS annual statistical report for clinicians. Methods: Incidence survival data are obtained from the Centers for Disease Control's National Program of Cancer Registries (NPCR) and National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) program. Survival data are obtained from NPCR. Mortality data are obtained from the National Vital Statistics System. Incidence and mortality rates are age-adjusted using the 2000 US population and presented per 100,000 population. Results: An annual average of 86,355 cases of primary malignant and nonmalignant CNS tumors were diagnosed over the period 2014-2018, corresponding to an average annual age-adjusted incidence rate of 24.25. The most commonly occurring malignant tumor was glioblastoma (14.3%), and the most common predominately nonmalignant tumor was meningioma (39%). Over the 2014-2018 period, there were 16,606 annual average deaths due to malignant primary CNS tumors, corresponding to an average annual age-adjusted mortality rate of 4.43. In this report we detail key incidence, survival, and mortality statistics for major primary CNS tumor histologies, highlighting relevant differences by age, sex, and race. Conclusions: This summary describes the most up to date population-based incidence of primary malignant and nonmalignant brain and other CNS tumors in the US, and mortality and survival for primary malignant tumors and aims to serve as a useful resource for clinicians. Published by Oxford University Press 2022.
Authors: K Aldape; M L Simmons; R L Davis; R Miike; J Wiencke; G Barger; M Lee; P Chen; M Wrensch Journal: Cancer Date: 2000-05-15 Impact factor: 6.860
Authors: Joe S Mendez; Quinn T Ostrom; Haley Gittleman; Carol Kruchko; Lisa M DeAngelis; Jill S Barnholtz-Sloan; Christian Grommes Journal: Neuro Oncol Date: 2018-04-09 Impact factor: 12.300
Authors: Monika E Hegi; Annie-Claire Diserens; Thierry Gorlia; Marie-France Hamou; Nicolas de Tribolet; Michael Weller; Johan M Kros; Johannes A Hainfellner; Warren Mason; Luigi Mariani; Jacoline E C Bromberg; Peter Hau; René O Mirimanoff; J Gregory Cairncross; Robert C Janzer; Roger Stupp Journal: N Engl J Med Date: 2005-03-10 Impact factor: 91.245
Authors: David N Louis; Arie Perry; Pieter Wesseling; Daniel J Brat; Ian A Cree; Dominique Figarella-Branger; Cynthia Hawkins; H K Ng; Stefan M Pfister; Guido Reifenberger; Riccardo Soffietti; Andreas von Deimling; David W Ellison Journal: Neuro Oncol Date: 2021-08-02 Impact factor: 13.029
Authors: Lisa Millgård Sagberg; Even Hovig Fyllingen; Tor Ivar Hansen; Per Sveino Strand; Aril Løge Håvik; Terje Sundstrøm; Alba Corell; Asgeir Store Jakola; Øyvind Salvesen; Ole Solheim Journal: J Neurooncol Date: 2022-08-27 Impact factor: 4.506